公开(公告)号：US20230330102A1

公开(公告)日：2023-10-19

申请号：US18310913

申请日：2023-05-02

Applicant: Genentech, Inc.

Inventor： Thomas Pillow ,  Jack Sadowsky ,  Leanna Staben ,  Steven Staben ,  Binqing Wei ,  Ingrid Wertz ,  Pragya Adhikari ,  Nicole Blaquiere ,  Peter Dragovich ,  Wayne Fairbrother

IPC: A61K31/551 ,  A61K47/54 ,  A61K47/68 ,  A61K47/65 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C12N9/00

CPC classification number: A61K31/551 ,  A61K47/545 ,  A61K47/68 ,  A61K47/65 ,  A61P37/06 ,  A61P35/00 ,  C07K16/2827 ,  C07K16/32 ,  C12N9/93 ,  C12Y203/02007

Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

公开(公告)号：US11666581B2

公开(公告)日：2023-06-06

申请号：US16194897

申请日：2018-11-19

Applicant: Genentech, Inc.

Inventor： Thomas Pillow ,  Jack Sadowsky ,  Leanna Staben ,  Steven Staben ,  Binqing Wei ,  Ingrid Wertz ,  Pragya Adhikari ,  Nicole Blaquiere ,  Peter Dragovich ,  Wayne Fairbrother

IPC: A61K31/551 ,  A61K47/54 ,  A61K47/68 ,  A61K47/65 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32 ,  C12N9/00

CPC classification number: A61K31/551 ,  A61K47/545 ,  A61K47/65 ,  A61K47/68 ,  A61P35/00 ,  A61P37/06 ,  C07K16/2827 ,  C07K16/32 ,  C12N9/93 ,  C12Y203/02007

Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

公开(公告)号：US20190175612A1

公开(公告)日：2019-06-13

申请号：US16194897

申请日：2018-11-19

Applicant: Genentech, Inc.

Inventor： Thomas Pillow ,  Jack Sadowsky ,  Leanna Staben ,  Steven Staben ,  Binqing Wei ,  Ingrid Wertz ,  Pragya Adhikari ,  Nicole Blaquiere ,  Peter Dragovich ,  Wayne Fairbrother

IPC: A61K31/551 ,  A61P35/00 ,  A61P37/06 ,  A61K47/65 ,  C12N9/00 ,  C07K16/32 ,  C07K16/28

Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.